ALZAMEND NEURO, INC. Accounts Payable
ALZAMEND NEURO, INC. (ALZN) had Accounts Payable of $725.85 thousand as of 2025-01-31, per its 10-Q filed 2025-03-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2025-03-10
- 2025-01-31: Accounts Payable, Current $725.85K.
- 2024-10-31: Accounts Payable, Current $1.25M.
- 2024-07-31: Accounts Payable, Current $2.88M.
- 2024-04-30: Accounts Payable, Current $2.93M.
| Period end | Accounts Payable, Current |
|---|---|
| 2025-01-31 | $725.85K 10-Q · filed 2025-03-10 |
| 2024-10-31 | $1.25M 10-Q · filed 2024-12-11 |
| 2024-07-31 | $2.88M 10-Q · filed 2024-09-11 |
| 2024-04-30 | $2.93M 10-Q · filed 2025-03-10 |
| 2024-01-31 | $3.83M 10-Q · filed 2024-03-25 |
| 2023-10-31 | $3.67M 10-Q · filed 2023-12-15 |
| 2023-07-31 | $2.74M 10-Q · filed 2023-09-13 |
| 2023-04-30 | $2.87M 10-K · filed 2024-07-30 |
| 2023-01-31 | $2.64M 10-Q · filed 2023-03-15 |
| 2022-10-31 | $648.12K 10-Q · filed 2022-12-12 |
| 2022-07-31 | $1.03M 10-Q · filed 2022-09-13 |
| 2022-04-30 | $1.16M 10-K · filed 2023-07-27 |
| 2022-01-31 | $464.89K 10-Q · filed 2022-03-15 |
| 2021-10-31 | $1.13M 10-Q · filed 2021-12-13 |
| 2021-07-31 | $1.07M 10-Q · filed 2021-09-13 |
| 2021-04-30 | $503.59K 10-K · filed 2022-07-19 |
| 2020-04-30 | $929.64K 10-K · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |